The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials
Abstract
Objective: To identify predictors of moderate‐to‐severe systemic lupus erythematosus (SLE) flare in 562 patients treated with standard therapy alone in phase III belimumab trials, and to evaluate the impact of standard therapies on preventing flares. Methods: Post hoc analysis assessed baseline demographics, disease activity, and biomarkers in patients with and those without flare at treatment weeks 24 and 52. Severe flare was defined by the modified SLE Flare Index (SFI) and the development of any new British Isles Lupus Assessment Group (BILAG) A domain score. Severe and moderate flare was defined by development of 1 new BILAG A domain score or 2 new BILAG B domain scores. Baseline characteristics associated with a ≥10% absolute difference or a ≥50% increase in flare rates were considered predictive. Results: Frequencies of flares over 52 weeks according to the SFI, any new BILAG A domain score, and 1 new BILAG A domain score or 2 new BILAG B domain scores were 23.7%, 23.1%, and 32.0%, respectively. Flare predictors by univariate analysis on all 3 indices at weeks 24 and 52 were a score ≥12 on the Safety of Estrogens in Lupus Erythematosus National Assessment version of the SLE Disease Activity Index (SELENA–SLEDAI); anti–double‐stranded DNA (anti‐dsDNA) positivity; proteinuria (≥0.5 gm/24 hours); BILAG renal, vasculitic, and hematologic scores; elevated C‐reactive protein levels; and B lymphocyte stimulator (BLyS) levels ≥2 ng/ml. Independent predictors by multivariate analysis at week 52 were SELENA–SLEDAI and/or BILAG renal involvement and anti‐dsDNA ≥200 IU/ml (on all 3 indices); SELENA–SLEDAI and/or BILAG neurologic and vasculitic involvement (on 2 indices: any new BILAG A domain score and 1 new BILAG A domain score or 2 new BILAG B domain scores); BLyS levels ≥2 ng/ml (on 2 indices: the SFI and 1 new BILAG A domain score or 2 new BILAG B domain scores); and low C3 level (on the SFI). Baseline medications did not significantly decrease or increase moderate‐to‐severe SLE flare risk. Conclusion: Patients who were receiving standard SLE therapy and had renal, neurologic, or vasculitic involvement, elevated anti‐dsDNA or BLyS levels, or low C3 had increased risk of clinically meaningful flare over 1 year. Hydroxychloroquine use was not predictive.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bertsias, G., Ioannidis, J. P. A., Boletis, J., Bombardieri, S., Cervera, R., Dostal, C., Font, J., Gilboe, I. M., Houssiau, F., Huizinga, T., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.070367 · Cited by 762
Ter Borg, E. J., Horst, G., Hummel, E. J., Limburg, P. C., & Kallenberg, C. G. M. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330505 · Cited by 572
Cited by
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215089 · Cited by 2,011
Self-citationSystemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 754
Self-citationNovel paradigms in systemic lupus erythematosus
Dörner, T., & Furie, R. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30546-x · Cited by 565
The BAFF/APRIL system in SLE pathogenesis
Vincent, F. B., Morand, E. F., Schneider, P., & Mackay, F. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.33 · Cited by 448
Chiche, L., Jourde‐Chiche, N., Whalen, E., Presnell, S., Gersuk, V., Dang, K., Anguiano, E., Quinn, C., Burtey, S., Berland, Y., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38628 · Cited by 420
Metadata
- Authors
- Petri, M. A., van Vollenhoven, R. F., Buyon, J., Levy, R. A., Navarra, S. V., Cervera, R., Zhong, Z. J., Freimuth, W. W., & Groups, O. B. O. T. B. A. B. S.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2013-07-26
- Volume
- 65
- Issue
- 8
- Pages
- 2143-2153
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1565295739
- Cited by
- 181
- References
- 2
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials. https://app.cochat.ai/papers/10.1002/art.37995
- The paper
- Petri, M. A., van Vollenhoven, R. F., Buyon, J., Levy, R. A., Navarra, S. V., Cervera, R., Zhong, Z. J., Freimuth, W. W., & Groups, O. B. O. T. B. A. B. S. (2013). Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials. Arthritis & Rheumatism. https://doi.org/10.1002/art.37995
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.